Image pharmaphorum Editor Views & Analysis Cleanrooms-on-demand: a more efficient future for pharma? The ‘as a service’ (AAS) model transformed the IT industry – making innovative technologies accessible to businesses without the high price point that would previously have been a barrier.< Views & Analysis Why should pharma invest in digital products for those livin... Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges. Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks. News Manny Montalvo video Load more results
Views & Analysis Cleanrooms-on-demand: a more efficient future for pharma? The ‘as a service’ (AAS) model transformed the IT industry – making innovative technologies accessible to businesses without the high price point that would previously have been a barrier.<
Views & Analysis Why should pharma invest in digital products for those livin... Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges.
Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.